A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Castle Biosciences Inc stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 9,476 shares of CSTL stock, worth $266,275. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,476
Previous 9,476 -0.0%
Holding current value
$266,275
Previous $270,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$17.4 - $31.47 $7,064 - $12,776
-406 Reduced 4.11%
9,476 $270,000
Q2 2024

Jul 29, 2024

BUY
$18.84 - $24.94 $17,935 - $23,742
952 Added 10.66%
9,882 $215,000
Q1 2024

Apr 25, 2024

BUY
$18.06 - $25.3 $13,328 - $18,671
738 Added 9.01%
8,930 $197,000
Q4 2023

Jan 30, 2024

BUY
$12.19 - $22.43 $17,005 - $31,289
1,395 Added 20.52%
8,192 $176,000
Q3 2023

Oct 25, 2023

BUY
$13.28 - $20.3 $38,631 - $59,052
2,909 Added 74.82%
6,797 $114,000
Q4 2022

Feb 01, 2023

SELL
$18.08 - $30.0 $650 - $1,080
-36 Reduced 0.92%
3,888 $91,000
Q3 2022

Nov 09, 2022

SELL
$22.51 - $34.32 $1,283 - $1,956
-57 Reduced 1.43%
3,924 $102,000
Q2 2022

Aug 09, 2022

SELL
$16.0 - $45.99 $3,104 - $8,922
-194 Reduced 4.65%
3,981 $87,000
Q1 2022

Apr 21, 2022

SELL
$33.17 - $46.98 $29,886 - $42,328
-901 Reduced 17.75%
4,175 $187,000
Q4 2021

Feb 01, 2022

SELL
$39.06 - $67.58 $2,929 - $5,068
-75 Reduced 1.46%
5,076 $218,000
Q3 2021

Nov 15, 2021

SELL
$60.13 - $77.6 $962 - $1,241
-16 Reduced 0.31%
5,151 $343,000
Q2 2021

Jul 30, 2021

BUY
$50.07 - $76.78 $8,011 - $12,284
160 Added 3.2%
5,167 $379,000
Q1 2021

May 03, 2021

BUY
$58.92 - $97.33 $184,537 - $304,837
3,132 Added 167.04%
5,007 $343,000
Q3 2020

Nov 06, 2020

BUY
$38.47 - $52.03 $72,131 - $97,556
1,875 New
1,875 $96,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $739M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.